{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:6041",
      "entity_text" : "duration",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02327",
      "entity_text" : "polymerase gene",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Unfortunately, with lamuvidine treatment and to a lesser extent also with entecavir treatment, the odds of YMDD mutations in hepatitis B virus polymerase gene increases with therapy duration, which in turns elevates the risk of HCC [XREF_BIBR].",
  "reading_complete" : "2020-08-02T11:17:18Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:13:40Z",
  "trigger" : "increases",
  "evidence" : [ "polymerase gene increases with therapy duration" ],
  "pmc_id" : "6185928",
  "score" : 0
}